Evidence Level
Stinging nettle root has a well-established evidence base in European phytotherapy, where it is an approved treatment for BPH in Germany and Austria (Commission E monograph). Safarinejad (2005) published the largest randomized controlled trial, enrolling 620 men with BPH who received either 600mg nettle root extract or placebo daily for 6 months. The nettle group showed significant improvements in IPSS score (from 19.8 to 11.8 vs. 19.2 to 17.7 for placebo), maximum urinary flow rate, and post-void residual volume. Lopatkin et al. (2005) studied the fixed combination of saw palmetto 160mg + nettle root 120mg (PRO 160/120) in 257 men over 48 weeks and found it comparable to finasteride 5mg for IPSS improvement with fewer sexual side effects. The SHBG-binding mechanism was characterized by Schottner et al. (1997), who identified specific lignans (secoisolariciresinol and its derivatives) that compete with testosterone for SHBG binding sites in vitro.